Commissural and Coronary Alignment Strategies in Transcatheter Aortic Valve Replacement: Success Rate and Risks Authors: Clara Fernandez-Cordón, Ignacio Amat-Santos Published: 2026 ABSTRACT Commissural alignment (CA) is becoming increasingly important in the lifetime management of younger patients with aortic stenosis undergoing transcatheter aortic valve implantation, potentially influencing coronary access, valve-in-valve feasibility and haemodynamics. Interest in the topic has led to a growing body of evidence, valve design improvements and optimised implantation techniques. In this review, we summarise the clinical impact of CA, its success rate and limitations, stressing the potential role of coronary alignment as opposed to CA. We also describe the techniques to achieve CA with the latest iterations of the most used transcatheter aortic valve implantation devices. Transcatheter aortic valve implantation (TAVI) has become the standard of care for a growing number of patients with severe aortic stenosis (AS) across all surgical risks.1,2 With its expansion to younger individuals, there is a high probability that they may need a second TAVI procedure during their lifespan.3,4 Furthermore, the likelihood of presenting with coronary artery disease (CAD) requiring coronary re-access after TAVI will increase. In this evolving scenario, some aspects of the index TAVI procedure have become increasingly important in current practice. One of them is commissural alignment (CA) between the commissural posts of the transcatheter aortic valve (TAV) and the commissures of the native aortic valve. CA facilitates coronary re-access, reduces the risk of coronary obstruction and allows leaflet modification techniques in case of re-do TAVI; it is also believed to improve valve haemodynamics, potentially increasing durability. While CA is routinely performed in surgical aortic valve replacement (SAVR), the alignment of the prosthetic and native commissures during TAVI is random unless specific CA techniques are implemented.5 CA also has pitfalls, especially in patients with certain anatomical features such as cusp asymmetry or coronary eccentricity. In these cases, coronary alignment (CoA) might be a better strategy to ensure coronary access.6 The aim of this review is to update and summarise the current evidence on CA and its impact and success rates, along with describing challenging scenarios in which CoA may be a better strategy. Device-specific techniques with the latest iterations of the most commonly used TAVI devices are described. Definitions In 2022, the ALIGN-TAVR consortium proposed a standardised definition of CA and other related concepts7 (Figure 1): Cusp symmetry is defined according to the inter-commissural angle of the largest cusp. Cusps are considered symmetric when this angle is 120–125°, meaning that each one of the three cusps corresponds to approximately one-third of the sinus aorta circumference. Higher inter-commissural angle means one sinus will be significantly larger than the other two, increasing cusp asymmetry, which is staged as mild (125–130°), moderate (130–135°) or severe (>135°). Cusp symmetry is defined according to the inter-commissural angle of the largest cusp. Cusps are considered symmetric when this angle is 120–125°, meaning that each one of the three cusps corresponds to approximately one-third of the sinus aorta circumference. Higher inter-commissural angle means one sinus will be significantly larger than the other two, increasing cusp asymmetry, which is staged as mild (125–130°), moderate (130–135°) or severe (>135°). The angle between the centre of the cusp and the coronary ostium is used to define coronary ostial eccentricity. When this angle is 0–10°, the coronary ostium is considered centred. As the ostium displaces from the centre of the sinus towards one of the commissures, this angle increases leading to growing levels of coronary eccentricity: mild (10–20°), moderate (20–30°) or severe (>30°). The angle between the centre of the cusp and the coronary ostium is used to define coronary ostial eccentricity. When this angle is 0–10°, the coronary ostium is considered centred. As the ostium displaces from the centre of the sinus towards one of the commissures, this angle increases leading to growing levels of coronary eccentricity: mild (10–20°), moderate (20–30°) or severe (>30°). Optimal CA is achieved when the commissures of the native valve and the commissural posts of the prosthetic valves are practically superimposed, with an angle between them of <15°. As the angle between the commissures grows, increasing degrees of commissural misalignment (CMA) can be defined: mild (15–30°), moderate (30–45°) or severe (45–60°). Optimal CA is achieved when the commissures of the native valve and the commissural posts of the prosthetic valves are practically superimposed, with an angle between them of <15°. As the angle between the commissures grows, increasing degrees of commissural misalignment (CMA) can be defined: mild (15–30°), moderate (30–45°) or severe (45–60°). Coronary overlap occurs when the commissural post of the prosthesis is in front of the coronary ostium, with an angle between them of <15°. Risk of coronary overlap has also been defined according to this angle as severe (<20°), moderate (20–35°) or no risk (>35°), based on the efficacy of a potential future bioprosthetic aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) technique.6 Coronary overlap occurs when the commissural post of the prosthesis is in front of the coronary ostium, with an angle between them of <15°. Risk of coronary overlap has also been defined according to this angle as severe (<20°), moderate (20–35°) or no risk (>35°), based on the efficacy of a potential future bioprosthetic aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) technique.6 Optimal CoA is achieved when the coronary ostia are as far as possible from the TAV commissural posts, minimising the risk of coronary overlap. CoA corresponds to positioning one of the posts at the bisector of the angle between both coronary arteries (if this angle is between 60° and 180°).6 Optimal CoA is achieved when the coronary ostia are as far as possible from the TAV commissural posts, minimising the risk of coronary overlap. CoA corresponds to positioning one of the posts at the bisector of the angle between both coronary arteries (if this angle is between 60° and 180°).6 Commissural Alignment and Related Concepts Clinical Impact and Reasons for Commissural Alignment The lifetime management of young patients with AS treated with TAVI should consider TAV haemodynamics and durability, easy coronary re-access and the feasibility of redo TAVI minimising the risk of coronary obstruction. CA can impact all these aspects. A summary of current data can be found in Table 1.8–14 Transcatheter Aortic Valve Haemodynamics and Durability In vitro studies have shown that CMA can impact fluid patterns in the aortic root, induce leaflet stress and reduce flow to the sinuses, therefore increasing flow stagnation.15–17 Simulated SAPIEN XT (Edwards) deployment in different orientations inside an aortic root model with severe AS, found that with increasing degrees of CMA there was also an increase in leaflet stress due to less expansion of the TAV.18 A bench model of valve-in-valve ACURATE neo (Boston Scientific) inside a Mitroflow surgical bioprosthesis (Sorin Group Canada) also showed increasing leaflet interaction and intraprosthetic aortic regurgitation (AR) with growing degrees of CMA.19 Several studies have evaluated the impact of CA in vivo, trying to discern whether these mechanisms are sufficient to impact TAV haemodynamics and durability in clinical practice. The retrospective RESOLVE registry reported that CMA was associated with a higher rate of transvalvular gradient progression at 30 days in patients treated with the balloon-expandable (BE) intra-annular SAPIEN 3 valve.8 However, a more recent study with the same valve did not find differences in gradient progression or mortality at 5 years between aligned and misaligned valves.9 Another multicentric cohort of patients treated with supra-annular self-expandable (SE) devices (Evolut PRO/PRO+ [Medtronic] and ACURATE neo2) did report higher mean gradients and greater progression of gradients at 1 year in patients with moderate/severe CMA.10 A retrospective cohort of patients treated with the Portico (Abbott Vascular) TAV consistently showed higher mean gradients post-TAVI when severe CMA was present.11 Higher rates of postprocedural mild central AR and greater AR progression at 1 year in subjects with CMA have been reported as well.5,10 Despite these early signs of accelerated TAV degeneration, no criteria for structural valve deterioration were met and clinical events did not differ or were not reported in these studies. Prospective investigations and longer follow-up data are needed to confirm the true impact of these findings. Hypo-attenuated leaflet thickening (HALT) is a marker of subclinical leaflet thrombosis that can be detected by post-TAVI cardiac CT. Since one of the consequences of CMA in bench studies is blood stagnation within the aortic sinus, increased thrombogenicity and HALT have been proposed as potential mechanisms of the early valve degeneration seen in patients with CMA. Kahn et al. reported a 40% incidence of HALT in a cohort treated with SAPIEN 3 when CMA was present (versus 28% in those with optimal CA), although this was not statistically significant.20 Recently, Jung et al. found that patients with HALT had a greater angle between native and prosthetic commissures, and more frequent severe CMA (37% versus 20%), than patients without HALT.21 However, the association of HALT with CA and its impact on valve durability require further investigation. It is important to note that most of the data supporting improved haemodynamic, lower rates of central AR and HALT in aligned valves are derived from studies with short-term follow-up. Whether this is really going to impact valve durability and long-term clinical outcomes is yet to be elucidated. The only published work with a 5-year follow-up of a cohort of patients treated with SAPIEN 3 valves failed to prove differences in gradient progression or mortality according to the degree of CA.9 This is an important gap in knowledge that should be emphasised. Coronary Re-access after Transcatheter Aortic Valve Implantation The prevalence of CAD in patients with severe AS undergoing TAVI ranges from 20% to 80%.22,23 Given this high prevalence and the expansion of TAVI to younger individuals, it is likely that the need for coronary angiography in patients with previous TAVI will increase. Factors impacting coronary access after TAVI depend on patient anatomy, device characteristics and procedural aspects such as implantation height and CA. Surgeons performing SAVR align the native and prosthetic commissures by direct visualisation, achieving almost universal CA. However, in the early years of TAVI, the orientation of the valve was random, with only 20% of cases meeting criteria for CA.5 As the degree of CMA increases, it becomes more likely that one of the commissural posts stands in front of the coronary ostia (a situation known as coronary overlap), acting as a physical barrier that can hinder selective coronary access. TAV design also plays an important role in the feasibility of coronary access. SE valves with longer stent frames, supra-annular leaflets and smaller cell design can complicate coronary access; on the other hand, shorter-frame BE devices, intra-annular leaflets and open cells favour easier coronary cannulation. Ochiai et al. assessed the incidence of unfavourable coronary access features by post-procedural CT (defined as ostium below the skirt of the TAV, or in front of the commissural post above the skirt).24 The incidence of these features was 35% for the left coronary artery (LCA) and 26% for the right coronary artery (RCA) after Evolut R/PRO implantation, but only 16% for the LCA and 8% for the RCA after SAPIEN 3. Table 1:Main Studies Assessing the Impact of Commissural Alignment after Transcatheter Aortic Valve Implantation Study Device Follow-up Results Haemodynamics Raschpichler et al. 20228SAPIEN 3/Ultra (Edwards)30 daysCMA was associated with increased mean gradients at 30 days (OR 1.3 per increase of 10° misalignment; p=0.01). No difference in rates of AR, mean gradient >20 mmHg or HALT.Unzue et al. 20259SAPIEN 35 yearsNo difference in peak (21.3 ± 5.9 mmHg) and mean gradients (10.3 ± 2.7 mmHg) between no/mild CMA and moderate/severe CMA. No differences in mortality.Amat-Santos et al. 202410Evolut PRO/PRO+ (Medtronic), ACURATE neo2 (Boston Scientific)1 yearCompared with patients with no/mild CMA, those with moderate/severe CMA had higher peak gradient (22 ± 9 versus 20 ± 9; p=0.001), greater progression of peak (p=0.002) and mean gradients (p=0.001) and higher rates of moderate/severe central AR (1.2% versus 0.4%; p=0.005)Tirado-Conte et al. 202211Portico (Abbott Vascular)At dischargePatients with severe CMA had higher mean gradient than those without severe CMA (9 [IQR: 7–11] versus 7 [IQR: 5–10] mmHg; p=0.037), and a trend toward higher peak gradients (18 [IQR: 14–20] versus 15 [IQR: 11–20] mmHg; p=0.128)Fuchs et al. 20185SAPIEN 3, LOTUS (Boston Scientific), Evolut R, Portico, ACURATE, CENTERA (Edwards)At dischargeHigher rate of mild central AR in patients with moderate/severe CMA versus those with no/mild CMA (6.3% versus 1%; p=0.03). No differences in gradients, aortic valve area, paravalvular leak or HALT. No differences in computational fluid dynamic coronary filling.Jung et al. 202421SE and BE valvesPost-TAVI CT (<12 months)Severe CMA was more frequent in patients with HALT than in controls (37% versus 20%; p=0.013). Severe CMA (OR 2.2; p=0.018) and more severe angular deviation (OR 1.02 per 1° deviation; p=0.018) were independent predictors of HALT. Coronary Re-access Barbanti et al. 202012 (RE-ACCESS study)Evolut R/PRO, SAPIEN 3/Ultra, ACURATE neo, Portico Implanted without CA techniquesCoronary cannulation before and after TAVIAfter TAVI, the rate of unsuccessful cannulation was 7.7% (4.7% in LCA, 4% in RCA), with semi-selective cannulation occurring in 12% in the LCA and 32% in the RCA. This was significantly higher in the Evolut group compared with the other valves (18% versus 0.04%; p=0.001). The main predictors of unsuccessful selective coronary cannulation were: Evolut valve, high implantation, small sinus of Valsalva.Costa et al. 202413 (RE-ACCESS 2 study)Evolut R/PRO/PRO+, ACURATE neo2 Implanted using CA techniquesCoronary cannulation after TAVI Post-TAVI CTUnsuccessful coronary cannulation in 5.5% (2.4% in LCA, 3.9% in RCA), with semi-selective cannulation occurring in 34% (10.2% in LCA, 21.3% in RCA). RCA selective cannulation was numerically higher in the ACURATE group. Coronary overlap with the TAV commissure and severe CMA were independently associated with unsuccessful selective cannulation in the Evolut recipients.Tarantini et al. 202214 (ALIGN-ACCESS study)SAPIEN 3, Evolut R/PRO, ACURATE neo SE implanted using CA techniquesCoronary cannulation after TAVISelective cannulation higher for SAPIEN 3 than for aligned or misaligned SE valves (95% versus 71% versus 46%; p<0.001). Unfeasible cannulation of at least one coronary was higher for misaligned SE than for aligned SE and SAPIEN valve (11% versus 3% versus 0%). SE misaligned valves (OR 4.59; p<0.01), sinus of Valsalva height and width were independent predictors of unfeasible/unselective cannulation. AR = aortic regurgitation; BE = balloon-expandable; CA = commissural alignment; CMA = commissural misalignment; HALT = hypo-attenuated leaflet thickening; LCA = left coronary artery; RCA = right coronary artery; SE = self-expandable; TAVI = transcatheter aortic valve implantation. Main Studies Assessing the Impact of Commissural Alignment after Transcatheter Aortic Valve Implantation AR = aortic regurgitation; BE = balloon-expandable; CA = commissural alignment; CMA = commissural misalignment; HALT = hypo-attenuated leaflet thickening; LCA = left coronary artery; RCA = right coronary artery; SE = self-expandable; TAVI = transcatheter aortic valve implantation. The RE-ACCESS study was the first prospective investigation on coronary access after TAVI.12 In patients treated with commercially available TAVI devices (Evolut R/PRO, SAPIEN 3/ULTRA, ACURATE neo and Portico) implanted without CA techniques, unsuccessful coronary cannulation occurred in 7.7% of subjects. Of note, all but one of these patients had received an Evolut device, and unsuccessful cannulation was 18% in the Evolut group. Higher implantation depth, TAV oversizing with respect to the aortic sinus, and Evolut TAV were independent predictors of unsuccessful cannulation. The RE-ACCESS 2 study was then designed to evaluate predictors of unsuccessful coronary cannulation after TAVI, using supra-annular SE devices (Evolut PRO/PRO+ and ACURATE neo2) implanted with CA techniques.13 Unsuccessful cannulation occurred in 5.5% of all patients and 7.5% of patients receiving Evolut (six of seven cases occurred in patients receiving Evolut). Severe CMA significantly impaired coronary re-access, but only among Evolut recipients. Therefore, the open-cell design of ACURATE seemed to ensure coronary re-access even when CMA was present. Similarly, the ALIGN-ACCESS study assessed the impact of CA in coronary access after TAVI with SAPIEN 3, Evolut PRO/R and ACURATE neo devices.14 Selective coronary access was higher for SAPIEN 3 than for aligned or misaligned SE supra-annular TAVs (95% versus 71% versus 46%) and cannulation was unfeasible in 11% of patients with misaligned SE devices. Misaligned SE valves, TAV oversizing with respect to the aortic sinus and lower sinus height were independent predictors of impaired cannulation. Table 2:Summary of Device-specific Radiopaque Markers, Commissural Alignment Techniques and Reported Success Rates with Current Devices Device Radiopaque Markers Technique (Transfemoral) Success Rate Evolut FX+ (Medtronic) Hat marker (delivery system)C-paddle in one of the commissures (outflow)Commissural postsRadiopaque dots at commissure sites (inflow) Flush port at 3 o’clockDescending aorta:LAO: hat marker to the right (outer curvature)Ascending aorta:CO: posts/dots II-I3C: Posts/dots I-I-I Rotation should be performed in the descending aortaEvolut R/PRO 86–92%14,31,34 Evolut FX+ 93–96%32,33Navitor Vision (Abbott) Commissural postsRadiopaque dots at commissure sites (inflow) Flush port at 12 o’clock (adopted, but no proven benefit in CA)Ascending aorta:CO: posts/dots II-I3C: posts/dots I-I-I Rotation should be performed in the descending aortaPortico (Abbott Vascular) 80%34ACURATE Prime (Boston Scientific) Commissural postsCommissural marks (distal delivery system) Insertion marker facing upAscending aorta:CO: posts/markers II-I3C: posts/markers I-I-I Gentle rotation can be performed in the ascending aortaACURATE neo2 (Boston Scientific) 80–100%14,34,37ALLEGRA (Biosensors) T-markers opposite to the commissures (outflow)Six radiopaque gold markers Flush port at 12 o’clock.Ascending aorta:CO: gold markers II-II-II3C: gold markers I-II-II-I ALLEGRA 80%40Myval (Meril Life) Commissural posts not visible with the valve crimped Crimp with one of the commissures in a specific CT-derived angle (OctaAlign [Meril Life] technique)Meril logo facing upMaintain position during valve advancement through the aorta Myval 60%41 Myval Octacor 70%43 3C = three-cusps view; CA = commissural alignment; CO = cusp-overlap (right–left) view; LAO = left anterior oblique. Summary of Device-specific Radiopaque Markers, Commissural Alignment Techniques and Reported Success Rates with Current Devices Hat marker (delivery system) Hat marker (delivery system) C-paddle in one of the commissures (outflow) C-paddle in one of the commissures (outflow) Commissural posts Commissural posts Radiopaque dots at commissure sites (inflow) Radiopaque dots at commissure sites (inflow) Flush port at 3 o’clock Flush port at 3 o’clock Descending aorta:LAO: hat marker to the right (outer curvature) Descending aorta: LAO: hat marker to the right (outer curvature) Ascending aorta:CO: posts/dots II-I3C: Posts/dots I-I-I Ascending aorta: CO: posts/dots II-I 3C: Posts/dots I-I-I Commissural posts Commissural posts Radiopaque dots at commissure sites (inflow) Radiopaque dots at commissure sites (inflow) Flush port at 12 o’clock (adopted, but no proven benefit in CA) Flush port at 12 o’clock (adopted, but no proven benefit in CA) Ascending aorta:CO: posts/dots II-I3C: posts/dots I-I-I Ascending aorta: CO: posts/dots II-I 3C: posts/dots I-I-I Commissural posts Commissural posts Commissural marks (distal delivery system) Commissural marks (distal delivery system) Insertion marker facing up Insertion marker facing up Ascending aorta:CO: posts/markers II-I3C: posts/markers I-I-I Ascending aorta: CO: posts/markers II-I 3C: posts/markers I-I-I T-markers opposite to the commissures (outflow) T-markers opposite to the commissures (outflow) Six radiopaque gold markers Six radiopaque gold markers Flush port at 12 o’clock. Flush port at 12 o’clock. Ascending aorta:CO: gold markers II-II-II3C: gold markers I-II-II-I Ascending aorta: CO: gold markers II-II-II 3C: gold markers I-II-II-I Commissural posts not visible with the valve crimped Commissural posts not visible with the valve crimped Crimp with one of the commissures in a specific CT-derived angle (OctaAlign [Meril Life] technique) Crimp with one of the commissures in a specific CT-derived angle (OctaAlign [Meril Life] technique) Meril logo facing up Meril logo facing up Maintain position during valve advancement through the aorta Maintain position during valve advancement through the aorta 3C = three-cusps view; CA = commissural alignment; CO = cusp-overlap (right–left) view; LAO = left anterior oblique. The results of these studies highlight the importance of CA to facilitate coronary re-access, especially in younger patients with supra-annular longer-frame SE devices, who might require lifetime management of CAD. Although the reported success rate of coronary access after TAVI remains high, in challenging cases left radial or transfemoral access can be used, and catheter choice might need to be adapted. On the contrary, the implantation of an intra-annular low-frame TAV in a sub-coronary position does not usually require any modification of the coronary canulation technique.23 RCA cannulation is usually more demanding than LCA, with higher rates of non-selective ostial engagement and longer cannulation times.12,13 Coronary Obstruction Risk and Feasibility of Valve-in-valve Transcatheter Aortic Valve Implantation Young patients treated with percutaneous or surgical bioprosthetic valves will likely require at least a second replacement during their lifespan. Valve-in-valve TAVI (both TAV-in-SAV and TAV-in-TAV) is feasible but exhibit high complexity and inherent challenges. One of the most feared complications is the acute impairment of coronary flow due to sinus sequestration or coronary obstruction, related to the neo-skirt formed by the leaflets of the first valve and the stent frame of the second. Understanding the 3D interactions between the valves, the aortic root and the coronary ostia is key to guiding preprocedural planning, avoiding coronary obstruction and preserving coronary access (Table 2). Several algorithms have aimed to assist in decision-making.6,25 A CT study of TAV-in-TAV with different combinations of Evolut and SAPIEN valves showed that coronary re-access was impaired in over one third of patients, but was more favourable when the first valve was a SAPIEN 3.26 When the TAV-in-TAV procedure is conducted emergently in the context of first valve embolisation, the probability of achieving CA of both prostheses drops to less than 10%.27 When the first valve is commissurally aligned, leaflet modification techniques such as bioprosthetic aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) can effectively reduce the risks of coronary obstruction by splitting the leaflet located in front of the coronary ostia.28,29 However, if the first valve is misaligned, BASILICA will not be effective. A different technique for the prevention and bail-out of coronary obstruction is chimney stenting, which can be used with good acute results regardless of CA, but has potential pitfalls if subsequent coronary re-access is needed.30 Implantation Techniques and Success Rates With Current Devices Current iterations of TAVs and their delivery systems incorporate device-specific radiopaque markers, aimed to locate the neo-commissures and guide CA techniques. Self-expandable Valves The basic principle of CA-oriented implantation techniques for SE devices relies on the adequate orientation of the TAV in the 3-cusps (3C) and cusp overlap (CO) coplanar fluoroscopic views. When the coronary cusps are symmetric, the native valve commissures are located 120° apart, and each of them is in front of the centre of the opposite cusp. In the CO view (usually right anterior oblique caudal), the right coronary cusp (RCC) and left coronary cusp (LCC) are superimposed to the right of the screen, leaving the non-coronary cusp (NCC) isolated to the left. This means the RCC-LCC commissure is located to the right of the screen. On the other hand, in the 3C view the RCC is in the middle of the screen, between the LCC to the right and the NCC to the left. Commissural Alignment with Evolut FX/FX+ (Medtronic) LAO = left anterior oblique. ©2025 Medtronic. All rights reserved. Used with the permission of Medtronic. All current SE TAV devices incorporate radiopaque markers at the commissural posts that can identify when the valve is crimped and after expansion. To achieve CA, we should aim for a II-I configuration of the commissural markers in the CO view, and a I-I-I configuration in the 3C view. Preprocedural CT is essential to CA, as it allows the identification of patient-specific implantation views. Evolut (Medtronic) The Evolut TAV has a C-paddle in the outflow that identifies the position of one of the commissural posts. When the valve is crimped, this C-paddle is mounted 90° clockwise from the fluoroscopic hat-marker of the delivery system. The new iterations of the Medtronic TAV (Evolut FX and FX+) incorporate three additional dot markers in the inflow of the valve that are positioned at the site of the commissural posts to improve CA and also mark the optimal 3 mm implantation depth. The Evolut FX+ valve also has three open windows, four-times the size of the valve cells, that are located between the commissures at a height consistent with the average coronary take-off height obtained from the Evolut low-risk trial.3 If CA is obtained, and assuming cusp symmetry and absence of significant coronary eccentricity, there will be one window in front of each coronary ostia, facilitating coronary re-access. The steps for CA with the Evolut FX/FX+ device are as follows (Figure 2): The delivery system should be inserted with the flush-port at 3 o’clock; this position should be reconfirmed before it enters the aortic arch. The delivery system should be inserted with the flush-port at 3 o’clock; this position should be reconfirmed before it enters the aortic arch. In the descending aorta and in left anterior oblique (LAO) projection, the hat-marker should be facing the external curve of the aorta (the right side of the screen). If the position is not correct, the system can be rotated up to one-quarter turn. In the descending aorta and in left anterior oblique (LAO) projection, the hat-marker should be facing the external curve of the aorta (the right side of the screen). If the position is not correct, the system can be rotated up to one-quarter turn. As the valve turns in the aortic arch and advances to the ascending aorta, the position of the hat-marker in the outer curvature of the aorta (now at the left side of the screen) should be verified near the aortic annulus in LAO. This means that in CO view, the hat-marker will be oriented at the centre-front, and the C-paddle will be pointing towards the LCC-RCC commissure at the right side of the screen. As the valve turns in the aortic arch and advances to the ascending aorta, the position of the hat-marker in the outer curvature of the aorta (now at the left side of the screen) should be verified near the aortic annulus in LAO. This means that in CO view, the hat-marker will be oriented at the centre-front, and the C-paddle will be pointing towards the LCC-RCC commissure at the right side of the screen. The position of the inflow radiopaque markers can be checked at initial valve flowering. In CO, one of them should be isolated to the right of the screen, while the other two are superimposed to the left (II-I configuration). In coplanar view, there should be one in the middle of the screen and one on each side (I-I-I configuration). The position of the inflow radiopaque markers can be checked at initial valve flowering. In CO, one of them should be isolated to the right of the screen, while the other two are superimposed to the left (II-I configuration). In coplanar view, there should be one in the middle of the screen and one on each side (I-I-I configuration). If the system is not well aligned, CA can be corrected by recapturing and pulling it back to the descending aorta, where it can be rotated up to one-quarter turn and re-advanced. Although the open windows can be seen when the TAV is correctly aligned, according to the manufacturer they should not be used to guide the CA technique, which has remained unchanged from the prior iterations of Evolut. Several studies have reported 86–92% rates of favourable CA (optimal CA or mild CMA) with the Evolut R/PRO devices using the flush port at 3 o’clock technique.14,31 First experience with the new Evolut FX device has reported even higher rates of CA, ranging between 93% and 96%, and significantly reduced risk of severe coronary overlap compared with the previous Evolut PRO+ (9% versus 23%).32,33 Although not endorsed by the manufacturer, 3 o’clock flush port insertion followed by rotation of the Evolut R/PRO device at the annulus plane as needed to achieve the desired commissural post orientation, led to 90% favourable CA in the COMALIGN trial.34 Navitor (Abbott) The Navitor TAV has three radiopaque commissural posts that can be used to achieve CA. The latest iteration, Navitor Vision, incorporates three additional dot markers at the inflow of the valve to indicate the neo-commissures and the recommended valve implantation depth of 3 mm, in a similar way to the Evolut FX/FX+ device. Although there are no official recommendations from the manufacturer, the most used technique for CA is as follows (Figure 3): Commissural Alignment with Navitor (Abbott) Reproduced with permission from Abbott. The Flex Nav delivery system (Abbott) is inserted with the flush port at 12 o’clock during transfemoral access. Although this practice is widely adopted and has been mentioned in previous reports, a study from Tirado-Conte et al. reported moderate/severe CMA in almost 70% of patients who received the former Portico TAV in this fashion.11,34 A more recent study by Miyashita et al. also showed that different initial deployment orientations had no impact on the incidence of severe coronary overlap.35 The Flex Nav delivery system (Abbott) is inserted with the flush port at 12 o’clock during transfemoral access. Although this practice is widely adopted and has been mentioned in previous reports, a study from Tirado-Conte et al. reported moderate/severe CMA in almost 70% of patients who received the former Portico TAV in this fashion.11,34 A more recent study by Miyashita et al. also showed that different initial deployment orientations had no impact on the incidence of severe coronary overlap.35 After reaching the aortic annulus, valve orientation is assessed in 3C view. At this point, there are three possibilities.36 First, if one of the posts is isolated (slit-like appearance) to the left of the screen, clockwise rotation of the delivery should be applied. Then, CA can be confirmed in the 2-cusps view by achieving a II–I configuration of the posts. Second, conversely, if in 3C view one of the posts is isolated to the right, counterclockwise rotation of the delivery should be applied. Third, if no post is isolated, the valve can be perfectly aligned (centre-front position of the post located in the middle) or severely misaligned (centre-back), and we will need the CO view to discern between the two. In case of misalignment, both clockwise or anticlockwise rotation can be applied to correct it. After reaching the aortic annulus, valve orientation is assessed in 3C view. At this point, there are three possibilities.36 First, if one of the posts is isolated (slit-like appearance) to the left of the screen, clockwise rotation of the delivery should be applied. Then, CA can be confirmed in the 2-cusps view by achieving a II–I configuration of the posts. Second, conversely, if in 3C view one of the posts is isolated to the right, counterclockwise rotation of the delivery should be applied. Third, if no post is isolated, the valve can be perfectly aligned (centre-front position of the post located in the middle) or severely misaligned (centre-back), and we will need the CO view to discern between the two. In case of misalignment, both clockwise or anticlockwise rotation can be applied to correct it. Of note, the valve should be rotated after retrieving it to the descending aorta, as the flexibility of the catheter does not allow for the rotation to transmit up to the aortic annulus. The COMALIGN trial reported 80% CA or mild CMA with a similar technique using the previous iteration of the Portico TAV.34 ACURATE (Boston Scientific) Although the ACURATE TAV was discontinued in May 2025, we are including it here because we will still come across the device in our clinical practice in the years to come. The ACURATE neo2 device had three radiopaque posts and free strut cells at the site of the neo-commissures. Insertion of the delivery system with the flush port at 6 o’clock was recommended, and then the orientation of the valve was assessed in the ascending aorta and gentle rotation was applied to achieve CA.34,37 With the last iteration, ACURATE Prime, the radiopaque markers and CA technique slightly changed (Figure 4): This new iteration does not have free cell struts, and commissural posts are aligned with three markers located distally in the delivery system. This new iteration does not have free cell struts, and commissural posts are aligned with three markers located distally in the delivery system. The delivery system must now be inserted with the CA marker facing up (which usually corresponds with the flush port at 1–2 o’clock), and the valve is advanced into the ascending aorta until the positioning marker is at the top of the pigtail. The delivery system must now be inserted with the CA marker facing up (which usually corresponds with the flush port at 1–2 o’clock), and the valve is advanced into the ascending aorta until the positioning marker is at the top of the pigtail. Then, orientation is first assessed in 3C view, with three possible scenarios, similar to those described for Navitor: First, if there is one post (slit-like appearance) and delivery marker isolated to the right of the screen, the valve must be slightly rotated clockwise. Correct CA can then be confirmed in CO. Second, and conversely, if there is one post and delivery marker isolated to the left, the valve must be slightly rotated counterclockwise. Third, in case there is no post isolated and the delivery markers have a I-I-I configuration, the CO view can confirm if the valve is aligned (post in the centre-front) or severely misaligned (post in the centre-back). In this last case, the valve can be rotated to either direction. Then, orientation is first assessed in 3C view, with three possible scenarios, similar to those described for Navitor: First, if there is one post (slit-like appearance) and delivery marker isolated to the right of the screen, the valve must be slightly rotated clockwise. Correct CA can then be confirmed in CO. Second, and conversely, if there is one post and delivery marker isolated to the left, the valve must be slightly rotated counterclockwise. Third, in case there is no post isolated and the delivery markers have a I-I-I configuration, the CO view can confirm if the valve is aligned (post in the centre-front) or severely misaligned (post in the centre-back). In this last case, the valve can be rotated to either direction. Commissural Alignment with ACURATE Prime (Boston Scientific) Reproduced with permission from Boston Scientific. Rotation must be done gently in 10° increments, allowing for the torque to translate. Then the operator must release their hands from the handle, so the torque dissipates. Once the orientation is correct, the valve can be advanced to the annulus plane and delivered in 3C view. In an unselected population treated with ACURATE neo2, successful CA was achieved in 80% of cases, with 17% mild CMA, and only 3% moderate or severe CMA.37 Other studies have reported CA or mild CMA in 88–100% of cases.14,34 As yet, there are no reports on CA success rate with the new ACURATE Prime. Other Self-expandable Devices Similar techniques using the CO view and device-specific commissural radiopaque markers have been described for other less commonly used SE devices, such as Hydra (SMT) and ALLEGRA (Biosensors).38–40 The supra-annular ALLEGRA device has three T-markers in the outflow that are aligned opposite to the valve commissures, and six radiopaque gold markers where the leaflets are sutured. Recently, a CA technique developed in a beating-heart model and then applied in 10 patients proved 80% success rate in achieving optimal CA without safety concerns.40 The valve was inserted with the flush port at 12 o’clock. In the ascending aorta, the gold marker configuration should be I–II–II–I in 3C and II–II–II in CO view. Once deployed, angiographic evaluation showing I–I–I configuration of the T-markers in 3C view and II–I configuration in CO view would be indicative of successful CA.40 Balloon-expandable Devices Commissural post radiopaque markers of BE devices cannot be adequately visualised when the valve is crimped, therefore the previously described techniques for SE valves are not applicable. CA techniques should be based on a patient-specific crimping orientation of the device, derived from a detailed assessment of the preprocedural CT. Commissural Alignment with Myval Octacor (Meril Life) Using the OctaAlign Technique LCC = left coronary cusp; NCC = non-coronary cusp; RCC = right coronary cusp. Reproduced with permission from Meril Life. Myval (Meril Life) The Myval TAV is the first BE alternative to the Edwards device that has become commercially available. Santos-Martínez et al. were the first to describe a CA technique that could be used for any TAV device, including BE devices.41 The Accurate Commissural Alignment (ACA) technique uses preprocedural CT to obtain a patient-specific angle, starting at the RCA (0) that is pointing at 12 o’clock. This angle is used to crimp the valve with a certain degree of clockwise or counterclockwise rotation, which must be maintained during TAV advancement along the vasculature, allowing CA when the valve rotates in the aortic arch.41,42 The technique’s proof of concept was performed with in silico and bench testing simulations, followed by in vivo implantation of the ACURATE neo device in 11 patients, with successful CA in all.42 Its efficacy was then proved in vivo in 10 patients with the Myval BE device, achieving CA in six and mild CMA in the remaining four cases (although three cases had right coronary overlap attributed to coronary eccentricity).41 The second iteration of Myval, Myval Octacor, has two rows of octagon-shaped cells and three commissural posts located 120° apart. Similar to the ACA technique, the OctaAlign technique (developed by Meril Life) provides a patient-specific CT-derived clock angle to crimp the valve with one of the posts oriented to the mid-right coronary cusp. The delivery system must then be inserted with the logo of the handle facing up, and this position must be maintained while advancing through the vascular anatomy. Assuming a 180° rotation in the aortic arch, the TAV will change its orientation from anteroposterior to posteroanterior, and the commissural post crimped towards the mid-RCC will end up pointing backwards towards the NCC-LCC commissure, achieving CA (Figure 5). In case of bicuspid anatomy, the commissural post must be crimped towards the origin of the RCA instead.43–45 OctaAlign has been tested in 32 patients treated with Myval Octacor, including tricuspid and bicuspid anatomy. CA or only mild CMA was achieved in 70% (including 77% of the bicuspid), while severe CA was present in four patients.43 Both the ACA and OctaAlign techniques avoid the need to torque the system inside the body, potentially reducing the risk of vascular and embolic events. SAPIEN To date, no technique has proved to be effective in reducing the risk of CMA with the SAPIEN TAV. Although the previously described ACA technique could potentially be used with any TAV, no dedicated studies have been conducted with SAPIEN.42 In the ALIGN-TAVR and Low Risk TAVR studies, intentional crimping of the SAPIEN 3 valve at different orientations did not improve CA.31,46 Assessment Methods The gold standard technique to assess CA after TAVI is post-procedural CT, but this is not routinely performed and is associated with unnecessary radiation and contrast administration. Fluoroscopic assessment of valve orientation after deployment is a more realistic approach in clinical practice and has shown relatively good concordance with CT. In the COMALIGN study, fluoroscopy showed an 86% accuracy to identify moderate to severe CMA with SE valves (ACURATE neo2, Evolut R/PRO and Portico).34 A method of assessing CA with the SAPIEN 3 valve has also been described, based on pre-procedural CT and intraprocedural aortography in CO and 3C views, with a strong correlation with post-TAVI CT.47 Challenging Scenarios, Limitations and Risks Commissural Alignment versus Coronary Alignment The rationale of CA greatly relies on symmetry. The geometry of TAV devices is symmetrical, with equal 120° angles between the three commissural posts and the nadir of the bioprosthetic leaflets located at 60° from each post. However, the geometry of the aortic root is not symmetrical: one cusp may be larger than the others (cusp asymmetry), or the coronary ostia might not be centred in the coronary cusp (coronary eccentricity). This is more prominent in bicuspid anatomies. Moderate to severe cusp asymmetry is present in 20% of tricuspid aortic valves and up to 65% of bicuspid aortic valves, the NCC being the more dominant. Moreover, moderate to severe coronary eccentricity occurs in 5.5% LCA versus 33% RCA in tricuspid anatomies and 6% LCA versus 23% RCA in bicuspid anatomies.48 In this imperfect real-life scenario, even optimal CA might not avoid some risk of coronary overlap. Some authors suggest that the focus should be on orienting the TAV commissural posts as far as possible from the coronary ostia. This is achieved by positioning one of the posts in the bisector of the angle between both coronary ostia – what is known as CoA. A coronary-aligned TAV would facilitate coronary re-access and ensure the feasibility and efficacy of BASILICA and other leaflet modification techniques. In practice, coronary ostia overlap view (as opposed to CO view) should be obtained by preprocedural CT analysis, and during valve implantation, positioning one of the commissural posts to the right of the screen in this view will lead to optimal CoA.6,48,49 Most techniques used for CA in BE valves can be adapted to achieve CoA using the coronary ostia overlap view (Figure 6). Commissural Alignment versus Coronary Alignment in a Bicuspid Aortic Valve RCA = right coronary artery. Redondo et al. analysed the pre-TAVR CT of 100 patients and performed virtual valve implantation to simulate commissural and coronary alignment.6 Risk of coronary overlap was defined as the angle between the coronary ostia and the nearer TAV post. With simulated CA, the risk of coronary overlap was moderate (20–35°), or severe (<20°) in 27% and 5% of cases, respectively. Most coronary overlap cases involved the more eccentric RCA. However, when coronary overlap was simulated, the mean angle between the coronary ostia and the nearest post was 48° (equal for both coronary arteries as expected) and coronary overlap decreased significantly: 95% of cases had no risk, and the remaining 5% had moderate risk. The results of this simulation study are consistent with those of the DA VINCI prospective study, that included 34 patients with type 1BAV with right–left raphe that underwent TAVI with BE devices and CA techniques.50 Despite 86% rate of CA/mild CMA, moderate to severe coronary overlap was seen in 14% of RCA and 45% of LCA, hindering selective bilateral coronary cannulation in more than one-third of patients. The optimal alignment strategy is yet to be elucidated. In patients with asymmetric features, including most bicuspid valves, CoA should probably be favoured to avoid significant coronary overlap. On the contrary, in symmetric anatomies both CA and CoA will have similar results in terms of valve orientation. It is unclear what constitutes an acceptable angle between the coronary ostia and the TAV posts, and a cut-off with clinical implications in coronary re-access, BASILICA procedures and valve haemodynamics has not been established. Future investigations are warranted to attempt to answer these questions. Feasibility and Potential Risks Not all TAV devices are made the same. Optimal rotation could not be applied at the level of the aortic root in 15% of Evolut R/PRO devices when compared to its contemporary ACURATE neo2 and Portico.34 The low metal-to-artery ratio of the ACURATE neo2 TAV has been shown to allow easy and safe rotation in the aortic annulus.37,51 On the contrary, and despite the improved flexibility of the last iteration of Evolut FX/FX+, the manufacturer currently recommends retrieving the valve to the descending aorta to torque it. The potential risks of TAV rotation inside the body should be considered and balanced with the benefit of achieving optimal valve orientation, especially in older patients with significant atherosclerosis. To date, rotation manoeuvres appear safe, and they have not been shown to increase periprocedural ischaemic stroke or vascular complications.34,37 However, these cannot be completely excluded. Moreover, alternative accesses are increasingly used in patients with femoral arteries unsuitable for TAVI. Most CA techniques and studies have been performed using transfemoral access, and there are no recommendations regarding flush port insertion from the axillary or carotid route, nor safety reports in this scenario. Future TAV iterations will continue to improve radiopaque markers’ visibility, delivery system flexibility and torqueability. At the same time, future investigations should continue to enhance implantation techniques, integrating these features with a personalised analysis of the pre-TAVI CT, with the goal of achieving optimal commissural or CoA for each patient and ultimately improving clinical outcomes. Conclusion Optimal CA is one of the landmarks of current TAVI practice, especially in younger patients with longer life expectancy. CA facilitates coronary access after TAVI, and it is key to reducing the risk of coronary obstruction during valve-in-valve procedures, allowing the effective use of leaflet modification techniques. It also impacts valve haemodynamics, including gradient progression, AR and thrombogenicity, although the long-term impact on valve durability is yet to be established. Current TAV device design and improved implantation techniques have allowed for high rates of CA, especially for BE valves, although these are not always implemented in clinical practice. Individualised pre-TAVI CT planning to obtain patient-specific implant angles is a current need. This patient-specific approach, including the need for coronary over CA in asymmetric and bicuspid anatomies, leading to personalised alignment protocols, is the next step for continued improvement of clinical outcomes.